About China Biotech Weekly
What is China Biotech Weekly?
China Biotech Weekly is a free intelligence briefing for US pharma business development teams, healthcare VCs, and BIOSECURE compliance professionals navigating the China biotech landscape.
Every issue breaks down the week's most consequential China-to-West licensing deals, translates new CDE filings from their original Mandarin, maps corporate ownership structures through Chinese registries, and tracks BIOSECURE enforcement timelines. The goal is simple: give time-constrained decision-makers the intelligence they need to evaluate Chinese biotech opportunities and risks — without having to read Chinese.
Why This Exists
38% of Big Pharma's $50M+ licensing deals in H1 2025 came from Chinese biotech companies. China-to-West out-licensing hit $137.7 billion. Meanwhile, the BIOSECURE Act was signed into law in December 2025, creating new compliance obligations for any US company working with Chinese CDMOs, CROs, or biotech partners.
US BD teams are making billion-dollar decisions based on English-language press releases and analyst reports. But the real signal — CDE filings, corporate registry data, SOE ownership chains, VIE structures — lives in Chinese-language databases that almost no one in the US reads natively.
China Biotech Weekly bridges that gap.
Written by Antony Tan
Antony reads CDE filings in their original Mandarin so you don't have to. MS Computational Biology at Harvard T.H. Chan School of Public Health, researcher at the Broad Institute of MIT & Harvard, published at NeurIPS 2025. BS Computer Science from the University of Toronto.
Trilingual in English, Mandarin Chinese, and Cantonese — one of the few people in the US who can navigate Chinese corporate registries (Tianyancha, GSXT), translate NMPA regulatory documents, and contextualize them for Western BD teams.
Our Methodology
Every briefing follows a rigorous process:
1. SOURCE
We monitor CDE filings, NMPA announcements, Chinese corporate registries (Tianyancha, GSXT), and deal announcements in both English and Chinese media.
2. TRANSLATE
CDE filings and Chinese regulatory documents are read by a native Mandarin speaker with computational biology training — not by machine translation alone. Technical terminology is verified against pharmacological and regulatory standards.
3. ANALYZE
Deal terms are benchmarked against comparable China-origin transactions. Corporate structures are mapped through Chinese holding company registries. BIOSECURE exposure is assessed against BCC designation criteria.
4. DELIVER
Analysis is packaged into actionable intelligence for time-constrained BD professionals. Every issue ends with concrete takeaways.
Independence & Ethics
China Biotech Weekly has no financial relationships with any Chinese biotech company, CDMO, CRO, or government entity. The author holds no stock positions in any company covered and does not accept consulting arrangements from companies under analysis. All analysis is independent. Where data is sourced from third-party reports or databases, the source is cited. Where deal values are estimated, methodology is noted.
This briefing provides intelligence and analysis — not investment advice, legal counsel, or policy advocacy. Readers should consult qualified professionals for specific business, legal, or compliance decisions.
Custom Intelligence Services
Beyond the weekly briefing, we provide custom deal evaluations, entity ownership mapping, and BIOSECURE exposure assessments. Learn more about our services →
Contact
For questions, feedback, or consulting inquiries: antony@chinabiointel.com
Connect on LinkedIn · Google Scholar · GitHub
Get the briefing every Thursday
Join pharma BD professionals, healthcare VCs, and BIOSECURE attorneys who read China Biotech Weekly every Thursday.